Patent · US Active

Osteoclast inhibitors for knee conditions

US9717747B2 · kind B2 · utility

47Cited by

59References

29Claims

0Family size

Assignee

ANTECIP BIOVENTURES II LLC · US

Inventors

Herriot Tabuteau · New York, US
Graeme Jones · Hobart, AU

Key dates

Filing date	Dec 2, 2016
Grant date	Aug 1, 2017
Priority date	—
Expiry date	Dec 2, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/663
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.